✅ New API: 6000+ US Stock Options End-of-Day Data with 40+ fields. Learn more

Lumosa Therapeutics Co. Ltd. (6535 TWO) stock market data APIs

NT$316.6228 -1.68(-0.5%)
as of September 18, 2025
Try our APIs with free plan!

Lumosa Therapeutics Co. Ltd. Financial Data Overview

Price chart is built with Anychart

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.

Prev. Close 316.6228
Open 314.9433
High 330.848
Low 315.3048
52 wk Range 122.5-400
Market Cap 53 655 M
Shares Outstanding 168 M
Revenue 37 251 K
EPS -0.89
Beta -0.054

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Lumosa Therapeutics Co. Ltd. data using free add-ons & libraries


Get Lumosa Therapeutics Co. Ltd. Fundamental Data

Lumosa Therapeutics Co. Ltd. Fundamental data includes:

  • Net Revenue: 37 251 K
  • EBITDA: -416 520 000
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Lumosa Therapeutics Co. Ltd. Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2025-08-07
  • EPS/Forecast: -0.46
GET THE PACKAGE

Get Lumosa Therapeutics Co. Ltd. End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE
Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat